Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 3
2(40.0%)
5Total
N/A(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04117984Completed

Swaziland HIV Incidence Measurement Survey 2

Role: collaborator

NCT05173324Phase 3Not Yet Recruiting

Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial

Role: collaborator

NCT02315690Phase 3Completed

Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland

Role: collaborator

NCT03397420Not ApplicableCompleted

Family-centered HIV Care, Viral Suppression and Retention in HIV-positive Children, Swaziland

Role: collaborator

NCT03254550Not ApplicableCompleted

PrEP Demonstration Study in Swaziland

Role: collaborator

NCT02909218Not ApplicableCompleted

MaxART: Early Access to ART for All in Swaziland

Role: collaborator

NCT01891799Completed

Swaziland Safe Generations

Role: collaborator

NCT02969161Completed

Safe Generations Plus: Swaziland PMTCT LTF Study

Role: collaborator

All 8 trials loaded